Indication: Pulmonary Hypertension
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Chronic Obstructive P
Drug Study
Principal Investigator: John McConnell, M.D.Norton Pulmonary Specialists
Sponsor: UNITED THERAPEUTICS CORPORATION
